CP-101
- Generic Name
- CP-101
CP101 for the Treatment of Ulcerative Colitis
Phase 1
Active, not recruiting
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: CP-101 + Placebo
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05852574
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)
Phase 2
Withdrawn
- Conditions
- ASDCP101SPROUTFecal TransplantAutismFinchFecal Microbiota TransplantAutism Spectrum DisorderFMTAutistic Thinking
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Finch Research and Development LLC.
- Registration Number
- NCT03829878
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Phase 2
Completed
- Conditions
- Clostridium Difficile Infection Recurrence
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Finch Research and Development LLC.
- Target Recruit Count
- 206
- Registration Number
- NCT03110133
- Locations
- 🇺🇸
Pinehurst, Pinehurst, North Carolina, United States
🇨🇦Calgary, Calgary, Alberta, Canada
🇺🇸Los Angeles, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath